Studies of the dysglycemic peptide, pancreastatin, using a human forearm model.
The physiologic effects of the chromogranin A peptide fragment, pancreastatin, were studied in six healthy Caucasian men, ages 25-46 years. Synthetic pancreastatin (human chromogranin A(273-301)-amide) was infused into the brachial artery of each subject to achieve a local concentration of approximately 200 nM over 15 minutes. Forearm blood flow was measured by strain-gauge plethysmography while (A-V)(glucose) was monitored by arterial and venous sampling. Pancreastatin infusion significantly reduced forearm glucose uptake (mean reduction +/- 1 SEM, 54 +/- 15%; P = 0.028) but did not alter forearm blood flow-indicating a metabolic, rather than hemodynamic, effect. Simultaneous infusion of pancreastatin with insulin (0.1 mU/kg/min) did not diminish insulin-induced forearm glucose uptake, suggesting pancreastatin is not simply a negative insulin modulator. The results of this study suggest that pancreastatin may contribute to the dysglycemia associated with type 2 diabetes and essential hypertension, two common human disease states in which plasma pancreastatin levels are elevated.
Cadman
Peter E
PE
Department of Medicine and Center for Molecular Genetics, University of California and VASDHS, San Diego, California 92161, USA. pcadman@ucsd.edu
Rao
Fangwen
F
Mahata
Sushil K
SK
O'Connor
Daniel T
DT
D000328:Adult; D001132:Arm / Q000098:blood supply*; D001783:Blood Flow Velocity / Q000187:drug effects; D001786:Blood Glucose / Q000378:metabolism; D053379:Chromogranin A; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology; D005947:Glucose / Q000493:pharmacokinetics; D006439:Hemodynamics; D006801:Humans; D008297:Male; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism; D010187:Pancreatic Hormones / Q000737:chemistry* / Q000502:physiology*
D001786:Blood Glucose; D053379:Chromogranin A; D010187:Pancreatic Hormones; C050836:pancreastatin; D005947:Glucose